CYP17A1 Recombinant Monoclonal Antibody

說明書

中文名稱：

CYP17A1重組抗體
貨號：

CSB-RA554990A0HU
規格：

￥1320
圖片：
Western Blot
Positive WB detected in: HepG2 whole cell lysate, Rat Heart whole cell lysate, Rat Brain whole cell lysate
All lanes: CYP17A1 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 58 kDa
Observed band size: 58 kDa

IHC image of CSB-RA554990A0HU diluted at 1:100 and staining in paraffin-embedded human testis tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.

Immunofluorescence staining of Hela Cells with CSB-RA554990A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品描述：

CSB-RA554990A0HU CYP17A1重組單克隆抗體是針對細胞色素P450 17A1酶研發的高特異性科研工具。CYP17A1作為類固醇生成關鍵酶，催化孕烯醇酮向17α-羥孕酮的轉化，在雄激素和糖皮質激素合成中發揮核心作用，其表達異常與多種內分泌相關疾病及腫瘤發生機制密切相關。本抗體采用重組蛋白免疫技術制備，經ELISA、Western Blot、免疫組化（IHC）和免疫熒光（IF）等多平臺驗證，可特異性識別內源性CYP17A1蛋白，在WB實驗中推薦1:500-1:5000的寬泛稀釋范圍，IHC和IF分別適用1:50-1:200及1:20-1:200的濃度梯度，實驗數據顯示在腎上腺、睪丸等組織樣本及培養細胞系中均呈現清晰的靶標識別信號。該抗體適用于探索類固醇激素代謝調控網絡、內分泌相關疾病模型中的酶活性變化以及腫瘤微環境中的激素合成機制研究，為生物化學、分子病理學及藥理學領域的研究者提供可靠的檢測工具，其嚴格的批次間一致性確保實驗數據的可重復性。
Uniprot No.：

P05093
基因名：

CYP17A1
別名：

Steroid 17-alpha-hydroxylase/17,20 lyase (EC 1.14.14.19) (17-alpha-hydroxyprogesterone aldolase) (EC 1.14.14.32) (CYPXVII) (Cytochrome P450 17A1) (Cytochrome P450-C17) (Cytochrome P450c17) (Steroid 17-alpha-monooxygenase), CYP17A1, CYP17 S17AH
反應種屬：

Human, Rat
免疫原：

A synthesized peptide derived from human Cytochrome P450 17A1
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號：

5A9
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200
IF	1:20-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis. Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen synthesis, involves an acyl-carbon cleavage. The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids biosynthesis pathway, are precursors of cortisol (Probable). Hydroxylates steroid hormones, pregnenolone and progesterone to form 17-alpha hydroxy metabolites, followed by the cleavage of the C17-C20 bond to form C19 steroids, dehydroepiandrosterone (DHEA) and androstenedione. Has 16-alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17-alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 bond to form 16-alpha-hydroxy DHEA. Also 16-alpha hydroxylates androgens, relevant for estriol synthesis. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase).
基因功能參考文獻：
1. The single nucleotide polymorphism rs11191548 near CYP17A1 is associated with high-density lipoprotein cholesterol and leptin in Chinese children. These findings provide evidence that HDL and leptin might mediate the process of CYP17A1 involved in hypertension. PMID: 29338791
2. - 34T>C polymorphism in CYP17A1 is associated with polycystic ovary syndrome. PMID: 29564739
3. We present one novel and one ultra rare gene variant with 17-OH deficiency, both described for the first time PMID: 29595516
4. identified a novel compound heterozygous CYP17A1 mutation His373Tyr (c.1117C>T) in a patient with 17alpha-hydroxylase/17,20-lyase deficiency. PMID: 29278670
5. the rs11191548 CYP17A1 gene mutation was associated with hypertension and the serum 25(OH) D levels in Han Chinese PMID: 29556032
6. T allele of rs743572 T polymorphism might predict high susceptibility to endometriosis, but it had no significant influence on characteristics and severity of endometriosis. PMID: 29995789
7. A polymorphism in the CYP17A1 gene was associated with the response to steroidogenesis inhibitors in Cushing's syndrome. PMID: 28665508
8. A single-point mutation at asparagine 202 in the active site pocket of CYP17A1, even when far from the heme, has profound effects on steroidogenic selectivity in androgen biosynthesis. In the mutant the 17alpha alcohol of OHPROG forms a H-bond with the proximal rather than terminal oxygen of the oxy-ferrous complex.When OHPREG was a substrate, the mutant was found to have weak H-bonding interaction with the proximal ox... PMID: 29283561
9. VT-464 reduces androgen receptor (AR) signaling more effectively than abiraterone in cultured PCa cells expressing T877A AR mutant PMID: 27748439
10. To our knowledge, this is the first study showing that the CYP17 T-34C and CYP19 TPMID: 29285776
11. the CYP17A1 polymorphisms could be a genetic risk factor for essential hypertension among the Yunnan Han Chinese population. PMID: 28537227
12. one CYP17A1 mutation (p.Arg362Cys) may share a common ancestry in Brazilian and present Spanish patients, while p.Trp406Arg may have arisen separately. PMID: 28376482
13. the CYP17CC genotype was significantly associated with developmental stuttering PMID: 28992603
14. A novel nonsense mutation in androgen receptor confers resistance to CYP17A1 inhibitor treatment in prostate cancer. PMID: 28036278
15. The mechanism of action, the efficacy and the clinical potential of CYP17A1 inhibitors in prostate cancer are also summarized. [review] PMID: 29372682
16. through mouse-to-human search and validation, we found that CYP17A1 is overexpressed in hepatocellular carcinomas and it has great potentiality as a noninvasive marker for hepatocellular carcinoma detection PMID: 27339169
17. Nominally significant parental genetic effects were found between the SNPs rs11191548 (CYP17A1) (paternal, beta = 2.78+/-1.49, P = 6.1x10-2 for SBP and beta = 3.60+/-1.24, P = 3.7x10-3 for DBP), rs17367504 (MTHFR) (paternal, beta = 2.42+/-0.93, P = 9.3x10-3 for SBP and beta = 1.89+/-0.80, P = 1.8x10-2 for DBP and maternal, beta = -1.32+/-0.60, P = 2.9x10-2 and beta = -1.97+/-0.77, P = 1.0x10-2, for SBP and DBP respecti... PMID: 29045471
18. Wild-type CYP17 allele when combined with LOH/MSI in steroid metabolism genes may play a role in ER and/or PR negative breast cancers. PMID: 28692125
19. Data suggest CYP17A1, with electron donor NADPH-P450 reductase, is inherently distributive enzyme but that some processivity is present; some 17alpha-hydroxy pregnenolone formed does not dissociate from CYP17A1 before conversion to dehydroepiandrosterone; CYP5A does not enhance reaction by decreasing k(off) of ligands of CYP17A1. (CYP17A1 = cytochrome P450, family 17, subfamily A, polypeptide 1; CYP5A = cytochrome b5) PMID: 28684414
20. we identified a novel (K144del) and a widely reported (Y329 fs) heterozygous mutations of CYP17A1 gene from a 17OHD patient. Haplotyping analysis showed the common mutation Y329 fs in China came from the same ancestor, which explains the reason that 17OHD was the second cause of congenital adrenal hyperplasia in China. PMID: 27150612
21. The activities of P450 17A1 are regulated by cyt b5 that enhances the 17,20-lyase reaction by promoting the coupling of P450 17A1 and cytochrome P450 reductase (CPR), allosterically. Cyt b5 can also act as an electron donor to enhance the 16-ene-synthase activity of human P450 17A1. PMID: 26976652
22. The results showed that CYP17A1 gene was not conclusively linked to either Insulin resistance (IR) or its associated increased androgen secretion in non-obese women with polycystic ovarian syndrome (PCOS). We propose that an increased sensitivity of insulin on the ovarian cells may be the predominant reason for the clinical effects and symptoms of androgen excess observed in non-obese PCOS patients in our region. PMID: 27748298
23. CYP17A1 defects were associated with amenorrhea, ovarian macrocysts and the diagnosis of 46, XX syndrome. PMID: 26920256
24. The discovery of these specific drug actions on steroidogenic enzyme activities would be valuable for understanding the regulation of androgens. PMID: 27395338
25. For the naturally occurring P450 17A1 mutations E305G and R347H, which impair 17,20-lyase activity, cytochrome b5 failed to rescue the poor coupling with 17-hydroxypregnenolone (2-4%). When the conserved active-site threonine was mutated to alanine (T306A), both the activity and coupling were markedly decreased with all substrates. PMID: 27426448
26. Mechanism of 17alpha,20-Lyase and New Hydroxylation Reactions of Human Cytochrome P450 17A1: 18O LABELING AND OXYGEN SURROGATE EVIDENCE FOR A ROLE OF A PERFERRYL OXYGEN. PMID: 27339894
27. The intensity of menopausal symptoms related to mood is higher among postmenopausal women presenting the GG genotype of the rs743572 polymorphism of the CYP17 A1 gene. PMID: 27117436
28. The analyzed polymorphisms in CYP17A1 do not seem to be correlated with clinical outcome of castration-resistant prostate cancer patients treated with abiraterone. PMID: 26954071
29. The common genetic variant rs2486758 in CYP17A1 was negatively associated with a biochemical response to and time to biochemical progression in patients treatment on abiraterone acetate and prednisone within metastatic castration-resistant prostate cancer. PMID: 27409606
30. CYP17 Gene Polymorphism is not associated with Breast Cancer. PMID: 27165202
31. CYP17 Gene Polymorphism is associated with Pancreatic Cancer. PMID: 27165211
32. CYP17 gene might be a risk factor for prostate cancer in males of advanced age. PMID: 26985923
33. Results show high level of CYP17A1 mRNA level in postmenopausal invasive ductal cancer which correlates with tumor prognosis. PMID: 27365044
34. No significant association between CYP17-34T/C polymorphism and insulin resistance was found in Thai polycystic ovary syndrome women, although the A2/X genotype group was statistically significantly younger than the A1/A1 genotype group. PMID: 26096606
35. the meta-analysis suggested that the CYP17 gene polymorphism was not associated with endometriosis risk. PMID: 25511200
36. Low apparent CYP17A1 activity is associated with elevated daytime ambulatory blood pressure when salt intake is high. CYP17A1 activity is heritable and diminished in the elderly. PMID: 26297028
37. The present meta-analysis confirmed the significant association between a polymorphism of the CYP17A1 gene and hypertension susceptibility. PMID: 25990650
38. CYP17A1 rs3824755 and rs743572 are associated with Alzheimer's disease in the Chinese Han population and act in combination with APOE e4. PMID: 26940238
39. Data indicate that cytochrome P450 17A1 (CYP17A1) first catalyzes pregnenolone (PREG) and then converts the 17-hydroxypregnenolone initial product to dehydroepiandrosterone, a process representing the first committed step in the biosynthesis of androgens. PMID: 26668369
40. Polymorphism single nucleotide of CYP17A1 gene is implicated to the development of high blood pressure. PMID: 26902494
41. The FMN domain outcompetes b5 for binding to CYP17A1 in the three-component system PMID: 26719338
42. Our study suggests no strong association between the CYP17A1 T27C and LEP -2548G>A polymorphisms and the incidence of breast cancer in Turkish women. PMID: 26407154
43. Interaction of novel oxazoline derivatives of 17(20)e-pregna-5,17(20)-diene with cytochrome P450 17A1 PMID: 26973185
44. The compound heterozygous mutation of p. Thr101Ilefs*2 and p. Thr306Ale is a new gene mutation of 17alpha-hydroxylase/17, 20-lyase deficiency. PMID: 26345865
45. genetic variants in the androgen-related genes CYP17A1 and JMJD1C might be associated with risk of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). PMID: 26414697
46. Thus, CYP17A1 may contribute to cardiac hypertrophy in this clinical condition. PMID: 26263970
47. Cytochrome-17 Gene Polymorphism is associated with Risk of Gall Bladder Stones and Cancer. PMID: 26225710
48. CYP17A1 mutation is associated with 17alpha-Hydroxylase/17-20 lyase deficiency leading to congenital adrenal hyperplasia. PMID: 25719302
49. Higher organochlorine pesticide levels and the A1A1 genotype of CYP17A1 in pregnant women may be considered as important aetiological factors in idiopathic small for gestational age. PMID: 25064838
50. The aim of the present study was to assess the association between CYP17A1 gene polymorphism and coronary artery disease in a Chinese Uygur population. PMID: 25592814
顯示更多

收起更多
相關疾病：

Adrenal hyperplasia 5 (AH5)
亞細胞定位：

Endoplasmic reticulum membrane. Microsome membrane.
蛋白家族：

Cytochrome P450 family
數據庫鏈接：

HGNC: 2593

OMIM: 202110

KEGG: hsa:1586

STRING: 9606.ENSP00000358903

UniGene: Hs.438016

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human